BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $23.36 +0.10 (+0.43%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatings About ARK Genomic Revolution ETF (BATS:ARKG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARKG alerts:Sign Up Key Stats Today's Range$22.96▼$23.5950-Day Range$22.66▼$27.1052-Week Range N/AVolume2.23 million shsAverage VolumeN/AMarket Capitalization$1.32 billionAssets Under Management$1.15 billionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.Read More… Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.55%0.57%0.52%Other Expenses0.00%0.57%0.49%0.48%0.53%Total Expense0.75%0.72%0.71%0.69%0.71%Fee Waiver0.00%-0.73%-0.52%-0.36%-0.57%Net Expense0.75%0.60%0.61%0.64%0.59% Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address ARKG ETF News HeadlinesUnusually active option classes on open November 14thNovember 15, 2024 | markets.businessinsider.comCathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The TableOctober 11, 2024 | msn.comBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.November 21, 2024 | Brownstone Research (Ad)ARK Genomic Revolution ETF (BATS:ARKG), Short Interest ReportOctober 4, 2024 | benzinga.comCathie Wood's Ark Invest Dumps Palantir Shares Amidst S&P 500 Inclusion And Extended AI AllianceSeptember 26, 2024 | msn.comCathie Wood’s Stock Shuffle: 1 Stock She’s Loving, 1 She’s LeavingSeptember 7, 2024 | msn.comSee More Headlines ARKG ETF - Frequently Asked Questions How have ARKG shares performed this year? ARK Genomic Revolution ETF's stock was trading at $32.81 on January 1st, 2024. Since then, ARKG stock has decreased by 28.8% and is now trading at $23.36. View the best growth stocks for 2024 here. Who are ARK Genomic Revolution ETF's major shareholders? Top institutional shareholders of ARK Genomic Revolution ETF include Main Management ETF Advisors LLC (4.30%), Main Management LLC (1.16%), Jane Street Group LLC and Barclays PLC (0.50%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ARK Genomic Revolution ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARK Genomic Revolution ETF investors own include Invesco QQQ (QQQ), ARK Innovation ETF (ARKK), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AbbVie (ABBV) and PayPal (PYPL). Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings39 Fund Statistics Assets Under Management$1.15 billion Average Daily Volume$2.68 million Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorThe Bank of NewYork Mellon Corporation AdvisorARK Investment Management LLC CustodianThe Bank of NewYork Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of NewYork Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume13,266 Put Options9,070 Call Options4,196 Miscellaneous Outstanding Shares56,500,000Beta1.99 Creation Unit50,000 Creation Fee$500.00 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 ARKG HoldingsTwist Bioscience (NASDAQ:TWST)Holding Weight: 8.37%Recursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 7.42%CRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 7.34%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 5.03%CareDx (NASDAQ:CDNA)Holding Weight: 4.77%Veracyte (NASDAQ:VCYT)Holding Weight: 4.51%Tempus AI (NASDAQ:TEM)Holding Weight: 4.26%Schrödinger (NASDAQ:SDGR)Holding Weight: 4.14%Beam Therapeutics (NASDAQ:BEAM)Holding Weight: 4.01%Intellia Therapeutics (NASDAQ:NTLA)Holding Weight: 3.89%Full Holdings DetailsARKG Sector ExposureARKG Industry Exposure This page (BATS:ARKG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
